Trial intelligence / Profile preview

Phase 3 comparison of LA-EP2006 versus Neulasta in breast cancer patients receiving TAC chemotherapy

2011-004532-58Phase 3Completed

Sponsor
Sandoz
Start
May 2012
Modality
Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
Countries
1
01

Overview

Phase 3, randomised, double-blind trial in breast cancer comparing LA-EP2006 with Neulasta (2 arms). Primary endpoint: Mean duration of Grade 4 neutropenia in Cycle 1. Started May 2012; status: completed.

02

Drugs

pegfilgrastim-bmezpegfilgrastim
03

Conditions

breast cancer

Beyond the preview

Go deeper on 2011-004532-58.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2011-004532-58.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call